In Vivo Effects of Myeloablative Alkylator Therapy on Survival and Differentiation of MGMTP140K-Transduced Human G-CSF-Mobilized Peripheral Blood Cells

Molecular Therapy

Volumn 13, Issue 5, 2006, Pages 1016-1026

  Cai, Shanbao ^a   Hartwell, Jennifer R ^a   Cooper, Ryan J ^a   Juliar, Beth E ^b   Kreklau, Emi ^c   Abonour, Rafat ^b   Goebel, W Scott ^a,b   Pollok, Karen E ^a,b  

^a RILEY HOSPITAL FOR CHILDREN   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BCNU; G CSF mobilized peripheral blood; gene therapy; hematopoietic stem cell; NOD SCID mice; O6 benzylguanine; O6 methylguanine DNA methyltransferase; SCID repopulating cell

Indexed keywords

6 O BENZYLGUANINE; CARMUSTINE; ENHANCED GREEN FLUORESCENT PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD TOXICITY; BONE MARROW CELL; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; DIABETES MELLITUS; DNA DAMAGE; DNA REPAIR; DRUG MEGADOSE; GENE EXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOID CELL; MOUSE; MYELOABLATIVE CONDITIONING; NONHUMAN; PERIPHERAL LYMPHOCYTE; SCID MOUSE; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD CELLS; CARMUSTINE; CELL DIFFERENTIATION; CELL SURVIVAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GRANULOCYTE COLONY-STIMULATING FACTOR; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RETROVIRIDAE; SEVERE COMBINED IMMUNODEFICIENCY; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 33645878910     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.11.017     Document Type: Article

References (36)

1. Park Y., and Gerson S.L. DNA repair defects in stem cell function and aging. Annu. Rev. Med. 56 (2005) 495
2. Sorrentino B.P. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat. Rev. Cancer 2 (2002) 431
3. Gerson S.L. Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol. 20 (2002) 2388
4. Quinn J.A., et al. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J. Clin. Oncol. 20 (2002) 2277
5. 6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol. Ther. 3 (2001) 78
6. Sawai N., Persons D.A., Zhou S., Lu T., and Sorrentino B.P. Reduction in hematopoietic stem cell numbers with in vivo drug selection can be partially abrogated by HOXB4 gene expression. Mol. Ther. 8 (2003) 376
7. Pollok K.E., et al. In vivo selection of human hematopoietic cells in a xenograft model using combined pharmacologic and genetic manipulations. Hum. Gene Ther. 14 (2003) 1703
8. 6-methylguanine-DNA-methyltransferase and HOXB4. Mol. Ther. 10 (2004) 862
9. Zielske S.P., Reese J.S., Lingas K.T., Donze J.R., and Gerson S.L. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. J. Clin. Invest. 112 (2003) 1561
10. 6-benzylguanine and temozolomide. Clin. Cancer Res. 5 (1999) 163
11. Neff T., et al. Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J. Clin. Invest. 112 (2003) 1581
12. Neff T., Beard B.C., Peterson L.J., Anandakumar P., Thompson J., and Kiem H.P. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 105 (2005) 997
13. Kreklau E.L., et al. Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea. Mol. Cancer Ther. 2 (2003) 1321
14. Persons D.A., et al. Successful treatment of murine {beta}-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood 102 (2003) 506
15. Davis B.M., Humeau L., and Dropulic B. In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication. Mol. Ther. 9 (2004) 160
16. Davis B.M., Koc O.N., and Gerson S.L. Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Blood 95 (2000) 3078
17. 6-benzylguanine-resistant mutant MGMT genes improve hematopoietic cell tolerance to alkylating agents. Prog. Exp. Tumor Res. 36 (1999) 65
18. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 57 (1997) 5093
19. Ragg S., et al. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res. 60 (2000) 5187
20. Jansen M., et al. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells. Cancer Gene Ther. 9 (2002) 737
21. 6-benzylguanine-resistant GFP-MGMT fusion protein as a novel in vivo selection marker. Exp. Hematol. 32 (2004) 709
22. Neff T., et al. Efficient gene transfer to hematopoietic repopulating cells using concentrated RD114-pseudotype vectors produced by human packaging cells. Mol. Ther. 9 (2004) 157
23. 6-alkylguanine-DNA alkyltransferase. Cancer Res. 54 (1994) 5123
24. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl. Acad. Sci. USA 87 (1990) 5368
25. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts. Hum. Gene Ther. 10 (1999) 1021
26. Kreklau E.L., Kurpad C., Williams D.A., and Erickson L.C. Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo. J. Pharmacol. Exp. Ther. 291 (1999) 1269
27. Kreklau E.L., Liu N., Li Z., Cornetta K., and Erickson L.C. Comparison of single- versus double-bolus treatments of O(6)-benzylguanine for depletion of O(6)-methylguanine DNA methyltransferase (MGMT) activity in vivo: development of a novel fluorometric oligonucleotide assay for measurement of MGMT activity. J. Pharmacol. Exp. Ther. 297 (2001) 524
28. Korbling M., and Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?. Blood 98 (2001) 2900
29. Couban S., et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100 (2002) 1525
30. Pollok K.E., et al. Differential transduction efficiency of SCID-repopulating cells derived from umbilical cord blood and granulocyte colony-stimulating factor-mobilized peripheral blood. Hum. Gene Ther. 12 (2001) 2095
31. Kreklau E.L., Limp-Foster M., Liu N., Xu Y., Kelley M.R., and Erickson L.C. A novel fluorometric oligonucleotide assay to measure O(6)-methylguanine DNA methyltransferase, methylpurine DNA glycosylase, 8-oxoguanine DNA glycosylase and abasic endonuclease activities: DNA repair status in human breast carcinoma cells overexpressing methylpurine DNA glycosylase. Nucleic Acids Res. 29 (2001) 2558
32. Wilpshaar J., et al. Similar repopulating capacity of mitotically active and resting umbilical cord blood CD34(+) cells in NOD/SCID mice. Blood 96 (2000) 2100
33. Gothot A., van der Loo J.C., Clapp D.W., and Srour E.F. Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34(+) cells in non-obese diabetic/severe combined immune-deficient mice. Blood 92 (1998) 2641
34. Reese J., Linguas K., Ksenich P., Sweeney C., Koc O., and Gerson S. Preliminary results of a phase I trial using retroviral gene transfer of G156A MGMT to protect hematopoiesis during BG and BCNU therapy of advanced malignancies. Mol. Ther. 9 (2004) S385
35. Miller A.D., Garcia J.V., von Suhr N., Lynch C.M., Wilson C., and Eiden M.V. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J. Virol. 65 (1991) 2220
36. Takatoku M., et al. Avoidance of stimulation improves engraftment of cultured and retrovirally transduced hematopoietic cells in primates. J. Clin. Invest. 108 (2001) 447